past
decad
highli
sensit
specif
test
viru
detect
develop
result
accur
detect
long
list
virus
associ
wheez
earli
life
risk
develop
asthma
exacerb
establish
diseas
human
rhinoviru
rv
respiratori
syncyti
viru
rsv
top
list
recent
discov
reemerg
virus
eg
human
metapneumoviru
hmpv
coronavirus
enteroviru
ev
also
contribut
acut
wheez
infanc
virusmedi
exacerb
howev
viral
infect
associ
acut
exacer
cofactor
includ
allerg
inflamm
airway
bacteria
describ
increas
sever
infect
probabl
detect
virus
airway
bacteria
associ
acut
wheez
ill
specif
coinfect
respiratori
virus
moraxella
catarrhali
hemophilu
influenza
andor
streptococcu
pneumonia
increas
risk
sever
respiratori
ill
exacerb
addit
antibiot
treatment
regimen
asthma
exacerb
could
materi
near
futur
sever
recent
studi
also
shown
respiratori
allergi
may
partner
certain
viral
infect
synergist
produc
airway
inflamm
increas
cold
asthma
sinc
current
safe
effect
antivir
rv
target
allerg
inflamm
may
prove
benefici
reduc
risk
sever
virusinduc
asthma
sever
possibl
immunopatholog
mechan
connect
viral
bacteri
infect
allergi
acut
asthma
discuss
follow
section
viral
identif
earli
childhood
wheez
ill
may
provid
prognost
inform
regard
short
longterm
consequ
short
term
rsvinduc
bronchiol
associ
longer
hospit
rvinduc
risk
reinfect
certain
virus
vari
exampl
strong
likelihood
rsv
reinfect
absenc
ongo
passiv
two
studi
found
risk
high
initi
infect
occur
within
first
year
life
fourth
certain
respiratori
virus
welldocu
associ
subsequ
asthma
develop
exacerb
sever
rsv
ill
earli
childhood
increas
risk
asthma
risk
develop
asthma
even
greater
rv
wheez
episod
earli
children
may
genet
risk
factor
wheez
rsv
rv
ev
infect
also
contribut
exacerb
asthma
especi
notabl
mani
commonli
use
polymeras
chain
reaction
pcr
base
test
distinguish
rv
ev
eg
viral
sequenc
analysi
specif
identifi
rv
preval
human
respiratori
viru
classifi
speci
b
c
speci
compris
number
differ
type
type
b
type
c
type
within
speci
consider
genet
antigen
heterogen
among
speci
c
phylogenet
closer
b
c
rva
rvb
origin
classifi
accord
sensit
capsidbind
drug
rvc
classifi
sequencebas
rv
circul
throughout
year
mani
geograph
area
appear
distinct
peak
incid
fall
infect
rate
remain
substanti
rest
year
adult
children
rv
frequent
identifi
viru
associ
acut
asthma
rv
enter
bodi
respiratori
rout
infect
replic
epitheli
cell
first
thought
rv
infect
upper
airway
known
also
infect
lower
one
propos
reason
asthmat
predispos
viral
infect
damag
epithelium
may
increas
suscept
infect
ultim
lead
airway
obstruct
cellular
mechan
involv
respons
includ
higher
intracellular
adhes
express
respiratori
epitheli
cell
disrupt
epitheli
barrier
function
impair
apoptosi
increas
cell
lysi
defici
respons
eg
interferon
ifn
enhanc
neutrophil
rv
infect
also
induc
proinflammatori
mediat
includ
interleukin
il
tumor
necrosi
regul
activ
normal
express
secret
rant
granulocytemacrophag
coloni
stimul
factor
gmcsf
addit
increas
airway
neutrophil
rvinduc
asthma
exacerb
also
associ
increas
airway
eosinophil
eo
airway
eo
bind
rv
may
particip
virusspecif
immun
respons
antigen
present
cell
eo
may
contribut
antivir
respons
rsv
clinic
signific
effect
unclear
eo
immunomodul
effect
includ
induc
cell
activ
eosinophil
cation
protein
ecp
upregul
express
respiratori
epitheli
note
rva
rvb
serotyp
use
receptor
pivot
role
movement
inflammatori
cell
rvc
type
bind
cadherinrel
correspond
gene
link
childhood
asthma
associ
sever
wheez
episod
earli
antigenicgenet
subtyp
rsv
b
exhibit
season
rsva
predomin
fallearli
winter
rsvb
winter
earli
rsva
associ
sever
ill
rsvb
character
milder
know
subtyp
patient
infect
may
therefor
clinic
treatment
prognosi
even
therapeut
prophylact
modal
becom
addit
caus
acut
wheez
bronchiol
infant
rsv
also
contribut
asthma
exacerb
children
rsv
infect
airway
induc
airway
inflamm
promot
airway
hyperrespons
airway
epitheli
cell
initi
respond
rsv
infect
releas
type
ifn
varieti
cytokin
chemokin
includ
rant
macrophag
inflammatori
protein
mip
monocyt
chemotact
protein
mcp
migrat
lymph
node
viral
antigen
present
cell
dendrit
cell
migrat
back
infect
epithelium
releas
mediat
eg
recruit
addit
inflammatori
cell
eg
cell
b
cell
granulocyt
neutrophil
eo
circumst
rsv
infect
may
promot
helper
bia
immun
respons
also
found
studi
compar
differenti
airway
inflammatori
respons
rsv
influenzainduc
asthma
exacerb
level
significantli
lower
rsvinduc
asthma
exacerb
compar
asthmat
infect
inde
weaker
respons
viral
infect
individu
may
lead
reduc
viral
clearanc
prolong
andor
seriou
diseas
rsv
infect
potent
induc
rant
eotaxin
particular
associ
increas
eosinophilia
rsv
diseas
sever
eotaxin
appear
key
compon
eotaxin
level
correl
close
eosinophil
degranul
ie
eosinophilderiv
neurotoxin
edn
ecp
pediatr
consequ
may
good
therapeut
target
asthma
eosinophilrel
diseas
host
factor
may
critic
determin
rsvinduc
diseas
sever
even
take
agerel
effect
currentrec
infect
air
pollut
allergen
exposur
host
genet
studi
found
sever
polymorph
relat
rsv
sever
includ
chemokin
receptor
bind
number
inflammatori
ccchemokin
includ
rant
promot
variant
thu
geneenviron
interact
may
contribut
suscept
virusinduc
diseas
ev
includ
polioviru
circul
mostli
summer
fall
temper
yearround
tropic
nonpolio
human
ev
newer
number
one
classifi
speci
eva
evb
evc
evd
evd
includ
serotyp
known
caus
diseas
human
although
new
first
isol
small
group
us
children
lower
respiratori
tract
infect
emerg
past
decad
import
respiratori
pathogen
report
north
america
europ
asia
associ
sever
respiratori
diseas
special
note
children
exactli
abl
caus
lower
respiratori
tract
diseas
current
unknown
viru
bind
specif
cell
receptor
found
predominantli
upper
respiratori
tract
howev
addit
mediat
requir
enter
evid
recent
strain
associ
lower
respiratori
tract
infect
may
gene
mutat
influenc
antigen
trophism
lower
airway
cell
rv
infect
allerg
sensit
synergist
increas
risk
wheez
atop
asthma
associ
reduc
virusinduc
ifn
respons
decreas
viral
increas
viral
studi
atop
asthmat
vs
nonatop
control
reduc
peripher
blood
mononuclear
cell
pbmc
ifn
furthermor
studi
found
bronchial
epitheli
cell
atop
asthmat
permit
increas
rv
replic
enhanc
cell
lysi
defici
releas
studi
children
allerg
asthma
treat
omalizumab
indic
neutral
immunoglobulin
e
ige
mediat
inflamm
lead
improv
ifn
respons
reduc
virusinduc
suggest
igemedi
inflamm
inhibit
antivir
respons
increas
risk
virusinduc
exacerb
asthma
sever
studi
shown
viral
infect
preced
bacteri
infect
upper
lower
airway
may
affect
diseas
sever
eg
increas
invas
pneumococc
diseas
high
rv
rsv
activ
may
occur
sever
reason
includ
virusinduc
express
airway
receptor
use
bacteria
cell
invas
disrupt
airway
epitheli
virus
bacteria
also
increas
releas
inflammatori
cytokin
mediat
epitheli
cell
leukocyt
caus
increas
inflamm
concomit
increas
symptom
risk
asthma
patient
stabl
asthma
even
exhibit
increas
colon
upper
lower
airway
proteobacteria
group
bacteria
predominantli
compos
gramneg
possibl
role
bacteria
earli
stage
asthma
demonstr
bisgaard
et
found
pneumonia
h
influenza
catarrhali
colon
upper
airway
earli
infanc
associ
increas
risk
recurr
wheez
lead
asthma
furthermor
wheez
ill
young
children
similarli
associ
detect
either
viral
bacteri
pathogen
rv
infect
promot
increas
detect
bacteri
pathogen
combin
rv
infect
detect
respiratori
pathogen
associ
greater
risk
ill
includ
exacerb
similarli
acut
wheez
ill
infant
schoolag
children
associ
viral
infect
airway
microbiota
domin
bacteri
rais
possibl
select
use
antibiot
vaccin
could
use
asthma
wheez
infant
control
studi
report
azithromycin
produc
clinic
benefit
infant
acut
whether
due
antimicrobi
effect
antiinflammatori
effect
macrolid
uncertain
given
repeat
antibiot
therapi
could
advers
effect
commens
bacteria
could
also
add
problem
drugresist
bacteria
research
need
longterm
effect
approach
improv
test
method
help
demonstr
infect
sever
respiratori
virus
import
contributor
asthma
exacerb
possibl
develop
asthma
earli
childhood
cofactor
genet
allerg
inflamm
airway
microbiom
also
modifi
risk
sever
viral
ill
exacerb
establish
asthma
practic
antivir
strategi
lack
may
opportun
prevent
treat
virusinduc
exacerb
reduc
airway
inflamm
perhap
target
microbi
cofactor
